Bylvay™ (odevixibat) is approved for the treatment of pruritus in PFIC in the U.S. and for PFIC in Europe. Elobixibat is approved for chronic constipation in Japan and Thailand. All other drugs and indications are currently investigational.
Among our core objectives is to advance scientific research for the benefit of patient care and reducing disease burden. We look to lead and support evidence generation to improve patient outcomes and impact of treatment.